bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
2023年12月19日 - 6:01AM
ビジネスワイヤ(英語)
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced
that it has commenced an underwritten public offering of
$150,000,000 of shares of its common stock. bluebird also intends
to grant the underwriters a 30-day option to purchase up to an
additional $22,500,000 of shares of its common stock to be sold in
the offering. The offering, actual size and terms are subject to
market conditions, and there can be no assurance as to whether or
when the offering may be completed. All shares in the offering are
to be sold by bluebird.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are
acting as joint book running managers for the offering. Raymond
James & Associates, Inc. is acting as co-manager for the
offering.
bluebird intends to use the net proceeds of the offering (i) to
support commercialization and manufacturing for its three approved
gene therapies, ZYNTEGLO, SKYSONA and LYFGENIA; and (ii) to fund
working capital and other general corporate purposes.
The offering is being made pursuant to an effective shelf
registration statement on Form S-3, including a prospectus, that
was filed with the U.S. Securities and Exchange Commission (the
“SEC”) on May 9, 2023 and was declared effective by the SEC on May
19, 2023. A preliminary prospectus supplement describing the terms
of the offering will be filed with the SEC and will form a part of
the effective registration statement. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the
public offering may be obtained, when available, by contacting
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at (866) 471-2526 or
by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204
or by email at prospectus-eq_fi@jpmorganchase.com . Before you
invest, you should read the preliminary prospectus supplement and
accompanying prospectus and the other documents that bluebird has
filed with the SEC for more complete information about bluebird and
the proposed offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or jurisdiction.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Examples of forward-looking statements in this press release
include, without limitation, statements regarding the consummation
of the offering, the terms of the offering and the anticipated use
of the net proceeds from the offering. All statements that are not
statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements are
based on historical performance and current expectations and
projections about our future financial results, goals, plans and
objectives and involve inherent risks, assumptions and
uncertainties, including internal or external factors that could
delay, divert or change any of them in the next several years, that
are difficult to predict, may be beyond our control and could cause
our future financial results, goals, plans and objectives to differ
materially from those expressed in, or implied by, the statements.
No forward-looking statement can be guaranteed. Forward-looking
statements in this press release should be evaluated together with
the many risks and uncertainties that affect bluebird bio’s
business, particularly those identified in the risk factors
discussion in bluebird bio’s Annual Report on Form 10-K, as updated
by our subsequent Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and other filings with the Securities and Exchange
Commission. These risks include, but are not limited to: delays and
challenges in our commercialization and manufacturing of our
products; we may encounter additional delays in the development of
our programs, including the imposition of new clinical holds, that
may impact our ability to meet our expected timelines and increase
our costs; the internal and external costs required for our ongoing
and planned activities, and the resulting impact on expense and use
of cash, has been, and may in the future be, higher than expected
which has caused us, and may in the future cause us to use cash
more quickly than we expect or change or curtail some of our plans
or both; substantial doubt exists regarding our ability to continue
as a going concern; our expectations as to expenses, cash usage and
cash needs may prove not to be correct for other reasons such as
changes in plans or actual events being different than our
assumptions; the risk that the efficacy and safety results from our
prior and ongoing clinical trials will not continue or be seen in
additional patients treated with our product candidates; the risk
of insertional oncogenic or other reportable events associated with
lentiviral vector, drug product, or myeloablation, including the
risk of hematologic malignancy; the risk that any one or more of
our products or product candidates, will not be successfully
developed or commercialized. The forward-looking statements
included in this press release are made only as of the date of this
press release and except as otherwise required by applicable law,
bluebird bio undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218251755/en/
Investors & Media Investors: Courtney O’Leary,
978-621-7347 coleary@bluebirdbio.com Media: Jess Rowlands,
857-299-6103 Jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
過去 株価チャート
から 4 2024 まで 5 2024
bluebird bio (NASDAQ:BLUE)
過去 株価チャート
から 5 2023 まで 5 2024